Iconovo publishes outcome of exercise of warrants series TO 1

Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Iconovo publishes outcome of exercise of warrants series TO 1

MARKN.

On 16 March 2026, the subscription period for exercise of warrants series TO 1 ("TO 1") for subscription of shares in Iconovo AB (publ) ("Iconovo" or the "Company") ended. The outcome shows that no TO 1 was used for subscription, resulting in an exercise rate of 0 percent. The subscription price for exercise of TO 1 corresponded to SEK 5.22 per share, which significantly exceeded the market price of Iconovo's share during the exercise period. Thus, no new shares will be issued by exercise of TO 1.

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort®. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Tapper Partners AB.

Datum	2026-03-17, kl 16:05
Källa	MFN

Bifogade filer

Iconovo publishes outcome of exercise of warrants series TO 1

LOGGA IN

Iconovo

Iconovo publishes outcome of exercise of warrants series TO 1